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Abstract
Background: There is a paucity of data on the in vivo efficacy of antibiotics for lethal Vibrio species. Analyses of
long-term surveillance datasets may provide insights into use of antibiotics to decrease mortality.
Methods: The United States Centers for Disease Control and Prevention (CDC) Cholera and Other Vibrio Illness
Surveillance (COVIS) dataset from 1990 to 2010, with 8056 records, was analysed to ascertain trends in antibiotics
use and mortality.
Results: Two-thirds of patients (5243) were prescribed antibiotics - quinolones (56.1 %), cephalosporins (24.1 %),
tetracyclines (23.5 %), and penicillins (15.4 %). Considering all Vibrio species, the only class of antibiotic associated
with reduced odds of mortality was quinolone (odds ratio 0.56, 95 % CI 0.46-0.67). Patients with V. vulnificus
treated according to CDC recommendations had lower mortality (quinolone alone: 16.7 %, 95 % CI 10.2-26.1;
tetracycline plus cephalosporin: 21.7 %, 16.8-27.5; no antibiotic: 51.1 %, 45.6-56.7; each p < 0.001). Cephalosporin
alone was associated with higher mortality (36.8 %, 28.2-46.3). For V. cholerae non-O1, non-O139, mortality rates
were lower for quinolone (0 %, 0–2.0) or tetracycline (4.3 %, 1.2-14.5) compared to no antibiotic (9.3 %, 6.4-13.3).
For all Vibrio species, mortality rates increased with number of antibiotics in the treatment regimen (p < 0.001).
Treatment regimens that included quinolone were associated with lower mortality rates regardless of the number
of antibiotics used. The main clinical syndromes of patients with V. vulnificus infection were septicaemia (53.1 %)
and wound infections (30.6 %). Mortality among V. vulnificus patients with septicaemia was significantly higher than for
other clinical syndromes (p < 0.001). In a multivariate regression model, mortality in cases with V. vulnificus was associated
with presence of pre-existing conditions (ORs ranged from 4.52 to 10.30), septicaemia (OR 2.64, 95 % CI 1.92-3.63) and no
antibiotic treatment (OR 7.89, 95 % CI 3.94-15.80).
Conclusion: In view of the lack of randomized control trials, surveillance data may inform treatment decisions for
potentially lethal Vibriosis. Considering all Vibrio species, use of quinolones is associated with lower mortality and penicillin
alone is not particularly effective. For the most lethal species, V. vulnificus, treatment that includes either quinolone or
tetracycline is associated with lower mortality than cephalosporin alone. We recommend treating patients who present
with a clinical syndrome suggestive of V. vulnificus infection with a treatment regimen that includes a quinolone.
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Background
The incidence of Vibrio infections, which can cause
acute diarrhoea and potentially serious complications
such as hypovolemic shock and septicaemia, continues
to rise in the United States [1]. Vibrio vulnificus is the
most lethal species, and there are limited data on the ef-
fectiveness of antibiotic use in V. vulnificus infections
[2]. In 1988, the Centers for Disease Control and Pre-
vention (CDC) in the United States established a surveil-
lance system for human infections caused by all species
of Vibrio known as “Cholera and Other Vibrio Illness
Surveillance” (COVIS) [3]. This surveillance information
has been used to inform healthcare providers and edu-
cate the public [4].
Clinical trials indicate that using an effective antibiotic
as an adjuvant therapy to treat V. cholerae reduces the
duration of diarrhoea [5, 6] and illness by almost 50 % in
patients with moderate and severe dehydration [6]. Stud-
ies of treatment efficacy for lethal Vibrio species such as
V. vulnificus, have inherent ethical difficulties and conse-
quently there are no randomised control trials (RCT) of
V. vulnificus in humans [2]. Animal model in vivo stud-
ies of antibiotic sensitivities to Vibrio infection may not
all be applicable to humans due to differences in phar-
macokinetic parameters [7]. Recommendations for V.
vulnificus infections from a recent review are largely
based on case reports or animal models [8]. The CDC
provides recommendations on treatment regimens for V.
vulnificus, V. parahaemolyticus and V. cholerae non-O1,
non-O139 [4]. However only recommendations on treat-
ing V. cholerae are based on a human RCT [4].
Observational studies on lethal Vibrio infections, using
established surveillance data over a long defined period
of time, may provide insights about the associations be-
tween the use of antibiotics and patient outcomes. For
example, Purcell et al. conducted a systematic review of
the use of prophylactic antibiotics in the prevention of
meningococcal disease and had to rely almost entirely
on surveillance data to support their use [9]. Dechet and
colleagues reviewed non-foodborne Vibrio infections
using COVIS data (1997 to 2006) and concluded that
the optimal antibiotic treatment for Vibrio infections re-
mains unknown [10].
We have analysed COVIS data from 1990 to 2010: (a)
to ascertain whether the COVIS data on antibiotic use
were consistent with the CDC treatment recommenda-
tions, and (b) to determine the relationship between
antibiotic treatment and mortality.
Methods
Study design and participants
Data were obtained from the CDC’s Enteric Diseases
Epidemiology Branch from case report forms submitted
to the COVIS during 1990 to 2010 [1]. COVIS data are
collected using a standardised form [3]. The COVIS
dataset included information on demographics, the
Vibrio species isolated and the source of the specimen,
clinical features (symptoms and signs), mortality, and
pre-existing conditions and treatments during the
30 days prior to the Vibrio illness. The dataset also in-
cluded information on whether or not the patient had
an antibiotic as treatment for the Vibrio illness (i.e. yes,
no, unknown), and if so, the name of the antibiotic/s.
Free text records of antibiotic names and some pre-
existing conditions and treatments (specifically malig-
nancy, immune disorders, proton pump inhibitors and
antacids) were reviewed by authors KCW and SJW inde-
pendently and classified using the Systematized Nomen-
clature of Medicine - Clinical Terms (SNOMED CT®)
system (SNOMED Premium Version 1.0) and then
reviewed jointly to reach consensus [11]. Pre-existing
conditions included heart disease, diabetes, liver disease,
alcoholism, malignancy, renal disease, haematological
disease and immune disorders. SNOMED CT® codes
were used to classify antibiotics into antimicrobial classes
(e.g. quinolone, cephalosporin), antimicrobial subclasses
(e.g. first, second and third generation cephalosporins)
and to standardise and review pre-existing conditions and
treatments (e.g. free text records of gastric surgery were
reviewed and those considered irrelevant, such as hernia
repair, were removed).
There were 8950 patients in the COVIS dataset, 6137
(68.6 %) of whom were recorded as having had antibi-
otics as treatment for their Vibrio illness. However, the
specific name of the antibiotic was not recorded for 894
(14.6 %). A sensitivity analysis, whereby results were
compared for analyses which either included or excluded
the 894 patients who had an unnamed antibiotic for the
Vibrio illness, was performed. There were no substantial
differences in terms of their epidemiological information
and mortality rates, and consequently the patients with-
out a named antibiotic were excluded from subsequent
analyses, resulting in a final sample size of N = 8056.
Statistical analysis
For the purposes of analysis, where antibiotic use was
recorded in COVIS as ‘unknown’ this was recoded as
‘no’ antibiotic used. Similarly, where data were missing
or recorded as ‘unknown’ for clinical signs or symptoms,
pre-existing conditions or treatments, or mortality, they
were recoded as ‘absent’ or ‘no’ for analysis. Based on re-
ported symptoms, patients with V. vulnificus were classi-
fied into the following clinical syndrome groups: (i)
septicaemia, characterised by the isolation of the organ-
ism from blood AND the presence of either fever or
shock; (ii) gastroenteritis, defined as the presence of
blood in stool, OR both diarrhoea and vomiting, OR any
gastrointestinal symptom AND the isolation of organism
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from stool; (iii) wound infection, characterised by cellu-
litis OR bullae OR fever in the absence of septicaemia,
where the organism was isolated from a wound only; or
(iv) other (not meeting any of the other criteria). Where
a patient met the criteria for more than one clinical syn-
drome, septicaemia took precedence over gastroenteritis,
and gastroenteritis over a wound infection.
Skewed continuous data were reported as medians
with an interquartile range (IQR). Associations between
demographics, antibiotic use and mortality were ex-
plored using unadjusted odds ratios with 95 % confi-
dence intervals. Chi-square analyses explored univariate
associations between factors such as antibiotic use and
mortality. The association between the total number of
antibiotics used and mortality was explored using the
linear-by-linear association chi-square test. A series of
univariate logistic regression models were conducted on
the sub-sample of patients with V. vulnificus to deter-
mine predictors of mortality. Variables in these regres-
sion analyses included age, gender, year of notification,
number of pre-existing conditions, clinical syndrome
presentation and type of antibiotic regimen (quinolone
only; quinolone and another antibiotic; at least one anti-
biotic, but not quinolone; or no antibiotic at all). Un-
adjusted odds ratios (OR) and 95 % confidence intervals
(CIs) were produced. A multivariate logistic regression
analysis was also conducted, including all of these vari-
ables, to produce adjusted ORs and 95 % CIs.
All analyses were conducted using SPSS (version 21;
IBM, 2012) and α was set at p < 0.05.
Ethics committee approval
All data were de-identified and the CDC confirmed that
ethics approval and informed consent were not applic-
able for this research.
Results
Of the 8056 patients, the median age was 47 years (IQR
33 to 62 years; N = 7773). Over two-thirds of the patients
were male (68.6 %; 5424/7905) and 98.3 % (7921/8056) of
the patients had only one Vibrio species identified. 127
(1.6 %) patients had two species and eight (0.1 %) patients
had three Vibrio species identified. The most commonly
identified species were V. parahaemolyticus, V. vulnificus,
V. alginolyticus and the non-O group strains of V.
cholerae (Table 1). The proportion of fatal cases differed
by Vibrio species, the greatest being in those with V.
vulnificus (Table 1). Cases of V. parahaemolyticus in-
creased dramatically over time, with peaks in 1998, 2004,
2006 and 2009–10, and there was a steady increase in
cases of V. alginolyticus (Fig. 1). Peak incidence typically
occurred during the summer months (June to August,
52.6 % of cases).
There were 5243 (65.1 %) patients who had an anti-
biotic as treatment for their Vibrio illness. The most
commonly used antibiotics were quinolones (56.1 %),
followed by cephalosporins (24.1 %), tetracyclines (23.5 %)
and penicillins (15.4 %). The use of quinolones in-
creased considerably after 1996 with peaks around
1997, 2005, and 2010, while the use of cephalosporin,
tetracycline and penicillin rose only slowly from 1990
to 2010 (Fig. 2).
A total of 602 (7.5 %) patients with a Vibrio illness
were recorded as deceased. Mortality was significantly
associated with being male (OR 2.10, 95 % CI 1.70-2.59).
Bullae (present in 7.3 % of cases), and shock (6.5 %) were
associated with significantly increased odds of mortality
(OR 8.67, 95 % CI 7.11-10.58; OR 28.49, 95 % CI 23.18-
35.01 respectively). Presence of at least one of the eight
pre-existing conditions (33.2 %) significantly increased
risk of death (OR 16.83, 95 % CI 13.18-21.49); in par-
ticular, a history of liver disease (10.6 %; OR 18.81, 95 %
CI 15.63-22.63) and alcoholism (8.9 %; OR 13.50, 95 %
CI 11.19-16.27).
The association between antibiotic classes (use of at
least one antibiotic of a particular class in a treatment
regimen) and mortality is presented by Vibrio species in
Table 2. Considering all patients, regardless of Vibrio
species, the only class of antibiotic associated with re-
duced odds of mortality was quinolone (OR 0.56, 95 %
Table 1 Vibrio species, mortality and gender distribution; United
States cases during 1990 to 2010 (N = 8056)
Vibrio species Total n (%) Mortality n (%) Male n (%)
V. parahaemolyticus 3474 (43.1) 29 (0.8) 2243 (66.1)
V. vulnificus 1599 (19.8) 491 (30.7) 1367 (86.4)
V. alginolyticus 874 (10.8) 11 (1.3) 589 (69.1)
V. cholerae non-O1, non-O139 763 (9.5) 41 (5.4) 474 (62.9)
V. fluvialis 445 (5.5) 13 (2.9) 243 (56.0)
V. cholerae O1 269 (3.3) 4 (1.5) 137 (51.1)
V. mimicus 211 (2.6) 5 (2.4) 116 (55.0)
V. hollisaea 131 (1.6) 1 (0.8) 79 (61.2)
P. damselab 63 (0.8) 3 (4.8) 45 (71.4)
V. cholerae O139 28 (0.3) 0 (0.0) 15 (57.7)
V. furnissii 19 (0.2) 1 (5.3) 13 (76.5)
V. metschnikovii 14 (0.2) 1 (7.1) 7 (53.8)
V. cincinnatiensis 2 (<0.1) 0 (0.0) 1 (50.0)
Species not identified 279 (3.5) 9 (3.2) 169 (61.7)
Other, no further information 28 (0.3) 0 (0.0) 16 (64.0)
Total n/a 602 (7.5) 5424 (67.3)
N.B. some patients had more than one species isolated, so numbers total
to N=8199
Proportions here are of the total patients, not total species identified
Information on gender was missing for n=151
aFormerly Vibrio hollisae, now Grimontia hollisae [2]
bFormerly Vibrio damsela, now Photobacterium damsela
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CI 0.46-0.67). This association held for those patients
with V. vulnificus (OR 0.58, 95 % CI 0.46-0.73), and V.
cholerae (non-O1, non-O139) (OR 0.12, 95 % CI 0.04-
0.40). Cephalosporin was associated with an increased
odds of mortality (OR 2.60, 95 % CI 2.16-3.13) overall,
and notably for V. parahaemolyticus (OR 6.41, 95 % CI
2.89-14.24). For those patients with V. vulnificus infec-
tion, use of the antibiotics quinolone, cephalosporin and
tetracycline was associated with significantly lower mor-
tality rate while use of penicillin was equivocal.
There was a statistically significant positive associ-
ation between the mortality rates and the number of
antibiotics used in a treatment regimen (linear by linear
association = 172.90, p < 0.001). Irrespective of Vibrio
species, a treatment regimen that included a quinolone
was always associated with lower mortality rate regard-
less of the total number of antibiotics in the treatment
regimen (Fig. 3a). Whether or not the treatment regimen
included a cephalosporin, tetracycline, or penicillin was
not associated consistently with the mortality rate
(Fig. 3b, c, d).
Tables 3 and 4 show the mortality associated with vari-
ous antibiotic regimens (including CDC recommenda-
tions) for treating Vibrio vulnificus and Vibrio cholerae
non-O1, non-O139 infections. Mortality rates for V. vul-
nificus were significantly lower in those patients taking
quinolone only or tetracycline combined with a third
generation cephalosporin as per CDC recommendations
(Table 3). Using quinolone as a reference, comparison
between the CDC recommended combination (i.e. tetra-
cycline and third generation cephalosporin) and other
combinations that included quinolone, showed no statis-
tically significant differences, except the comparison
with taking a cephalosporin alone or a penicillin alone
or no antibiotic (p = 0.002, p = 0.024, p < 0.001 respect-
ively; Table 3). For V. cholerae (non O1 and non-O139),
only use of quinolone alone was associated with a sig-



















V. parahaemolyticus V. vulnificus V. alginolyticus
V. cholerae non-O1, non-O139 V. cholerae O1 V. cholerae O139






















Quinolones Cephalosporins Tetracyclines Penicillins
Fig. 2 Patterns of antibiotic use in the United States for patients with Vibrio illness: 1990 to 2010 (N = 5243)
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Considering only V. vulnificus, 53.1 % (839/1581) had
septicaemia, 4.5 % (71) had gastroenteritis, 30.6 % (484)
had a wound infection, and 11.8 % (187) had other clin-
ical presentation. Eighteen cases were excluded because
they could not be classified as information on the sam-
ple source was missing. Cases with septicaemia were
more likely to fatal (40.6 %, 341/839), followed by 28.9 %
(54) of those with other presentation, 28.2 % (20) of
those with gastroenteritis and 14.3 % (69) of those with
wound infections (p < 0.001). A series of logistic regres-
sion analyses with single predictor variables was con-
ducted, with year of notification dichotomised into 1990
to 1996 versus 1997 to 2010 to reflect the significant in-
crease in quinolone use from 1996 observed in Fig. 2.
The crude odds of mortality amongst those with V. vul-
nificus increased significantly with the number of pre-
existing conditions (see Table 5). In comparison to
wound infections, all other clinical syndromes conferred
increased odds of dying. Compared to quinolone alone,
an antibiotic regimen without quinolone, and no anti-
biotic use at all were associated with increased odds of
mortality. The multivariate analysis on mortality for pa-
tients with V. vulnificus infection showed the same patterns
for number of pre-existing conditions. Gastroenteritis
no longer conferred significantly greater odds of dying
over wound infections, but septicaemia and other clin-
ical syndrome did. In the adjusted model, quinolone
alone remained superior in comparison to no antibiotic
treatment.
Discussion
Using this large surveillance dataset covering more than
two decades, we determined that the two most import-
ant factors associated with mortality are the particular
Vibrio species and the class of antibiotic used. Quin-
olone is the only class of antibiotic associated with lower
mortality in all Vibrio species, regardless of the number
of antibiotics used in a treatment regimen. In potentially
lethal V. vulnificus infections, the use of quinolone alone
or the combination of tetracycline and third generation
cephalosporin had the lowest mortality which is in-line
with the current CDC recommendations.
Penicillin was the least effective antibiotic for vibriosis
according to our analysis. In 1984, the USA National
Institutes of Health recommended use of penicillin or
tetracycline to treat V. vulnificus based on in vitro sen-
sitivity studies [12]. Morris cautioned that in vitro data
can be misleading, and recommended against using
penicillin as a single antibiotic to treat V. vulnificus in-
fections in humans [13]. In 2002, Tang conducted a
study on mice and reported that quinolones as single
antibiotics were as effective as cefotaxime-minocycline
(third generation cephalosporin and tetracycline) in
combination [7]. However Tang cautioned that results
of animal models may not be applicable to humans due
to differences in pharmacokinetic parameters [7]. Our
findings support Morris’s caution against penicillin as a
single antibiotic (i.e. penicillin was not associated with
reduced mortality) and substantiate Tang’s previous find-
ings in animals (i.e. third generation cephalosporin and
Table 2 Mortality and antibiotic use, by type of Vibrio illness
(N = 8056)






Received at least one
antibiotic
65.1% 64.6% 0.98 (0.82-1.16)
At least one quinolone 37.4% 24.9% 0.56 (0.46-0.67)
At least one
cephalosporin
14.5% 30.6% 2.60 (2.16-3.13)
At least one tetracycline 14.5% 25.1% 1.98 (1.63-2.40)
At least one penicillin 9.5% 15.8% 1.78 (1.41-2.25)
V. parahaemolyticus n = 3445 n = 29
Received at least one
antibiotic
56.5% 65.5% 1.46 (0.68-3.15)
At least one quinolone 39.8% 37.9% 0.93 (0.44-1.97)
At least one
cephalosporin
6.6% 31.0% 6·41 (2.89-14.24)
At least one tetracycline 7.3% 20.7% 3.29 (1.33-8.16)
At least one penicillin 4.6% 3.4% 0.75 (0.10-5.53)
V. vulnificus n = 1108 n = 491
Received at least one
antibiotic
86.6% 68.2% 0.33 (0.26-0.43)
At least one quinolone 37.1% 25.5% 0.58 (0.46-0.73)
At least one
cephalosporin
42.3% 33.2% 0.68 (0.54-0.85)
At least one tetracycline 47.5% 27.3% 0.42 (0.33-0.52)
At least one penicillin 18.5% 17.7% 0.95 (0.72-1.25)
V. alginolyticus n = 863 n = 11
Received at least one
antibiotic
76.0% 36.4% 0.18 (0.05-0.62)
At least one quinolone 29.7% 18.2% 0.53 (0.11-2.46)
At least one
cephalosporin
23.6% 18.2% 0.72 (0.15-3.35)
At least one tetracycline 10.0% 0.0% n/a
At least one penicillin 19.1% 9.1% 0.42 (0.05-3.33)
V. cholerae non-O1, non-
O139
n = 722 n = 41
Received at least one
antibiotic
66.1% 39.0% 0.33 (0.17-0.63)
At least one quinolone 39.3% 7.3% 0.12 (0.04-0.40)
At least one
cephalosporin
9.4% 19.5% 2.33 (1.04-5.25)
At least one tetracycline 12.3% 19.5% 1.72 (0.77-3.85)
At least one penicillin 9.6% 7.3% 0.75 (0.23-2.48)
n/a not applicable
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tetracycline in combination are more effective). More re-
cently Shaw and colleagues evaluated the antimicrobial
susceptibility of V. vulnificus recovered from two commer-
cial environmental areas and found that V. vulnificus dem-
onstrated resistance to penicillin [14], which may further
confirm the inefficacy of penicillin.
For V. cholerae (non-O1, non-O139), quinolone was
the only class of antibiotic associated with lower mortality
rate. For V. parahaemolyticus, quinolone and penicillin
appeared to have equivocal odds ratios for mortality; while
cephalosporin and tetracycline were associated with higher
mortality. However, the total number of deaths from V.
cholerae was 41 and for V. parahaemolyticus was 29, so
conclusions are limited.
Generally, the mortality rate increased along with the
number of antibiotics used in the treatment regimen.
We postulated that seriously ill patients were given more
than one antibiotic and were associated with increased
Fig. 3 a Mortality by use of quinolone in treatment regimen. b Mortality by use of cephalosporin in treatment regimen. c Mortality by use of
tetracycline in treatment regimen. d Mortality by use of penicillin in treatment regimen. ** indicates a statistically significant difference at p <
0.001, * indicates a statistically significant difference at p < 0.05. n = 3132 used one antibiotic; 1305 used two antibiotics; 652 used three
antibiotics; 154 used four antibiotics
Table 3 Mortality associated with various antibiotic regimens in the treatment of V. vulnificus (n=1599)
Na Crude mortality % (95% CI) Comparison with Quinolone only p value
CDC treatment recommendationb
Quinolone only 14/84 16.7 (10.2-26.1) -
Tetracycline + cephalosporin (all generations) 49/226 21.7 (16.8-27.5) 0.329
Tetracycline + 3rd generation cephalosporin 39/182c 21.4 (16.1-28.0) 0.366
Other combinations
Quinolone + cephalosporin (all generations) 24/98 24.5 (17.1-33.9) 0.195
Quinolone + tetracycline 15/95 15.8 (9.8-24.4) 0.874
Quinolone + cephalosporin + tetracycline 15/87 17.2 (10.7-26.5) 0.920
Other single antibiotics
Tetracycline alone 30/145 20.7 (14.9-28.0) 0.456
Cephalosporin alone (all generations) 39/106 36.8 (28.2-46.3) 0.002
Penicillin alone 18/54 33.3 (22.2-46.6) 0.024
No antibiotic 156/305 51.1 (45.6-56.7) <0.001
an=399 patients with less common antibiotic regimens not included here, thus numbers do not total to n=1599
bhttp://www.cdc.gov/vibrio/vibriov.html (accessed 27 June 2014): “Doxycycline (100 mg PO/IV twice a day for 7-14 days) and a third-generation cephalosporin (e.g.
ceftazidime 1-2 g IV/IM every eight hours) are generally recommended. A single agent regimen with a fluoroquinolone such as levofloxacin, ciprofloxacin or
gatifloxacin, has been reported to be at least as effective in an animal model as combination drug regimens with doxycycline and a cephalosporin”
cn=182 patients are a subset of the n=226 patients with a tetracycline combined with a cephalosporin
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number of antibiotics in their treatment; hence, their
mortality rate was higher possibly because they were
sicker instead of due to the larger number of antibiotics
used. We found that quinolone was the only antibiotic
associated with reduced mortality rate regardless of the
number of antibiotics in the patient’s regimen.
We have shown an increase in use of quinolone after
1996 but this may be a reflection of increased use in the
wider community. Linder and colleagues have reported a
three-fold increase in prescribing quinolone between
1995 and 2005 in the United States adult population
[15]. This increase in quinolone prescription may not
necessarily reflect increased recognition of the efficacy
of this antibiotic amongst prescribers or the promulga-
tion of treatment guidelines. It is likely that marketing,
advertising and provision of sample antibiotics might
have partly contributed to the increase in prescribing of
newer antibiotics [15–17].
We found associations between liver disease, alcohol-
ism and previous ill health and mortality with all species.
For V. vulnificus the number of pre-existing conditions
was associated with increased odds of mortality in both
unadjusted and adjusted models. Others have found that
patients with liver disease or alcoholism are at higher
risk of V. vulnificus infection [10, 18, 19]. This may be
Table 4 Mortality associated with various antibiotic regimens in
the treatment of V. cholerae non-O1, non-O139 (n=763a)












Penicillin alone 1/38 2.6 (0.5-13.5) 1.000




FET fisher’s exact test
an=188 patients with less common antibiotic regimens not included here, thus
numbers do not total to n=763
bhttp://www.cdc.gov/cholera/treatment/antibiotic-treatment.html (accessed 27
June 2014): “Antibiotic choices should be informed by local antibiotic
susceptibility patterns. In most countries, doxycycline is recommended as
first-line treatment for adults, while azithromycin is recommended as first-line
treatment for children and pregnant women”
Table 5 Predictors of death in cases of V. vulnificus in the United States during 1990 to 2010
Fatal N (%) Non-fatal N (%) Crude OR (95% CI) Adjusted OR (95% CI)
Age, mean (SD) 56.6 (13.5) 58.0 (17.8) 0.995 (0.989-1.001) 0.99 (0.98-0.998)
Gender
Female 72 (15.2) 135 (12.6) reference reference
Male 402 (84.8) 939 (87.4) 0.80 (0.59-1.09) 0.70 (0.49-1.000)
Year of notification
1990 – 1996 103 (21.7) 194 (18.1) reference reference
1997 – 2010 371 (78.3) 880 (81.9) 0.79 (0.61-1.04) 0.99 (0.73-1.34)
Pre-existing conditions
0 41 (8.6) 397 (37.0) reference reference
1 107 (22.6) 277 (25.8) 3.74 (2.53-5.53) 4.52 (2.92-6.99)
2 194 (40.9) 227 (21.1) 8.28 (5.69-12.03) 10.30 (6.72-15.78)
3 or more 132 (27.8) 173 (16.1) 7.39 (4.99-10.95) 9.31 (5.93-14.62)
Clinical presentation
Wound 68 (14.3) 406 (37.8) reference reference
Gastroenteritis 20 (4.2) 49 (4.6) 2.44 (1.36-4.35) 1.52 (0.77-3.01)
Septicaemia 333 (70.3) 493 (45.9) 4.03 (3.01-5.40) 2.64 (1.92-3.63)
Other 53 (11.2) 126 (11.7) 2.51 (1.67-3.79) 1.69 (1.04-2.74)
Antibiotic treatment
Quinolone only 13 (2.7) 68 (6.3) reference reference
Quinolone and other/s 106 (22.4) 335 (31.2) 1.66 (0.88-3.12) 1.44 (0.73-2.84)
Antibiotic/s, not quinolone 208 (43.9) 534 (49.7) 2.04 (1.10-3.77) 1.84 (0.95-3.56)
None 147 (31.0) 137 (12.8) 5.61 (2.97-10.62) 7.89 (3.94-15.80)
Wong et al. BMC Infectious Diseases  (2015) 15:226 Page 7 of 9
because V. vulnificus uses transferrin-bound iron, which
is usually abundant in these patients, for growth [18,
20]. Another hypothesis about the increase mortality in
the presence of liver disease is that the shunting of por-
tal blood containing V. vulnificus infection around a dis-
eased liver may lead to septicaemia [21]. The main
clinical syndromes in patients with V. vulnificus infec-
tion were septicaemia and wound infections. Mortality
among V. vulnificus patients with septicaemia was sig-
nificantly higher than for other clinical syndromes. A
treatment regimen that included quinolone was associ-
ated with lower mortality compared with cephalosporin
alone or penicillin alone or no antibiotic at all. We rec-
ommend that patients who present with a clinical syn-
drome suggestive of V. vulnificus infection be treated
with a regimen that includes a quinolone.
There are a number of limitations to this study that re-
late to the underlying surveillance data collection. For
example, non-cholera vibriosis only became nationally
notifiable in USA from 2007 onwards [22]. Several per-
tinent details regarding use of antibiotics were not re-
corded systematically such as timing or order of
antibiotic use. There were 894 patients who had an un-
named antibiotic for the Vibrio infection. Cephalospo-
rins could not be categorised into the four generations
due to the small subgroup size. This may have contrib-
uted to the paradoxical observation in Table 2 where a
treatment regimen that had included a cephalosporin
was associated with increased mortality rate in V. chol-
era (non-O1 and non-O139) and V. parahaemolyticus in-
fections, but reduced mortality elsewhere. The dataset
did not detail specific cause of death, but an infection
such as Vibrio is likely to have been significant. Further
characterisation of liver disease (type and severity) was
not possible due to the inconsistency of these data in the
COVIS dataset. Finally, it is possible that the use and ef-
fectiveness of different antibiotics reflect changes in the
antibiotic sensitivities of the organism, however we are
unable to explore this with the data available in the
COVIS dataset.
Determining the optimal antibiotic regimen for a po-
tentially lethal infection is difficult because randomised
controlled trials may not be possible and in vitro or ani-
mal models may not be easily applied in patients. In this
context, systematic experience from detailed surveillance
data may inform treatment decisions. However informa-
tion from surveillance data is only as good as the data
collected. The COVIS dataset may not have included
every Vibrio cases and reporting may have been biased
towards more severe cases [22]. It is important that cli-
nicians provide detailed and timely data to surveillance
programs such as COVIS. Publication of findings from
surveillance data may help encourage clinicians to pro-
vide specific data regarding antibiotic use. Surveillance
authorities must be encouraged to simplify and refine
the data collection tools and seek more specific informa-
tion on classes of antibiotics and the time frame of their
use so that the influence of these important factors can
be reported and analysed.
Conclusions
Surveillance of large numbers of affected individuals
over longer periods of time appears to be a reasonable
method of determining antibiotic use and outcome pat-
terns. Vibrio infection remains a serious condition with
significant mortality. Adjuvant antibiotic therapy in
addition to basic care with fluids has an important role.
The use of quinolones may reduce risk of death in pa-
tients with V. vulnificus and V. cholerae (non-O1 and
non-O139). For V. vulnificus, which has the highest
mortality rate, a treatment regimen which is in line with
the CDC recommendations i.e. that includes either quin-
olone alone, or tetracycline and a third generation ceph-
alosporin is associated with lower mortality. Penicillin
alone is not particularly effective. We recommend treat-
ing patients who present with a clinical syndrome sug-
gestive of V. vulnificus infection with a treatment
regimen that includes a quinolone.
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